Clinical trial
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial…
NCT00407407 · Celgene, Industry · Terminated
Key facts
| NCT number | NCT00407407 |
|---|---|
| Title | ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma |
| Official title | A Phase I Dose Escalation Study of ABI-007 With Carboplatin TM as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma |
| Lead sponsor | Celgene, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms |
| Intervention type | Drug |
| Interventions | ABI-007, Carboplatin |
| Enrollment | 6 |
| Start date | Nov 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Dec 5, 2006 |
| Last update posted | Oct 18, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: